Q2 2020 Press Release
(WorldNews Argentina)

CytoSorbents Reports Record Second Quarter 2020 Financial Results CytoSorbents posts record Q2 2020 Total Revenue of $9.8 million, including a 61% increase in Product Sales to $9.5 million, with $30 million in trailing 12-month Product Sales MONMOUTH JUNCTION, N.J., August 4, 2020 - CytoSorbents Corporation(NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb®blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports its full financial and operational results for the quarter ending June 30, 2020. Second Quarter 2020 Financial Results: Total revenue for Q2 2020 was approximately $9.8 million, a 58%...